Armand Glassman to Antineoplastic Agents
This is a "connection" page, showing publications Armand Glassman has written about Antineoplastic Agents.
Connection Strength
0.201
-
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood. 2005 Jun 15; 105(12):4573-5.
Score: 0.038
-
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood. 2005 Mar 15; 105(6):2281-6.
Score: 0.037
-
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol. 2004 Apr; 125(2):187-95.
Score: 0.035
-
A unique, complex variant philadelphia chromosome translocation in a patient with typical chronic myelogenous leukemia. Arch Pathol Lab Med. 2001 Mar; 125(3):437-9.
Score: 0.028
-
Hemostatic abnormalities associated with cancer and its therapy. Ann Clin Lab Sci. 1997 Nov-Dec; 27(6):391-5.
Score: 0.023
-
Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res. 1997 Apr 15; 57(8):1487-94.
Score: 0.022
-
Morphologic, cytogenetic, and molecular abnormalities in therapy-related acute promyelocytic leukemia. Am J Clin Pathol. 2005 Jun; 123(6):840-8.
Score: 0.010
-
Antitumor effects of abrin and ricin used singly and in combination with cisplatin. Ann Clin Lab Sci. 1984 Jan-Feb; 14(1):10-20.
Score: 0.009